Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Nasopharyngeal Carcinoma 8Esophageal Squamous Cell Carcinoma 7Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 5Small Cell Lung Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Neoplasm Metastasis 2Muscle Invasive Bladder Cancer (MIBC) 2Biliary Tract Neoplasms 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Salivary Gland Malignant Neoplasms 1SCLC, Extensive Stage 1Rectal Neoplasms 1Rare Tumour 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Non Small Cell Lung Cancer 1Neoplasms 1NSCLC 1Muscle-invasive Bladder Urothelial Carcinoma 1Melanoma 1Esophageal Neoplasms 1

Interventions

toripalimab 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Non Squamous Non Small Cell Lung Cancer × toripalimab × Clear all
NCT05962021 2023-08-01

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

Peking University People's Hospital

Phase 2 Not yet recruiting
126 enrolled
Thoracic

Non Squamous Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡